AbbVie
ABBV
3,110 hedge funds and large institutions have $183B invested in AbbVie in 2023 Q3 according to their latest regulatory filings, with 175 funds opening new positions, 1,277 increasing their positions, 1,280 reducing their positions, and 106 closing their positions.
72% more call options, than puts
Call options by funds: $3.77B | Put options by funds: $2.19B
65% more first-time investments, than exits
New positions opened: 175 | Existing positions closed: 106
30% more funds holding in top 10
Funds holding in top 10: 172 → 224 (+52)
11% more capital invested
Capital invested by funds: $165B → $183B (+$18.4B)
1% more funds holding
Funds holding: 3,078 → 3,110 (+32)
0.19% more ownership
Funds ownership: 69.45% → 69.64% (+0.19%)
0% less repeat investments, than reductions
Existing positions increased: 1,277 | Existing positions reduced: 1,280
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$883M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$441M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$213M |
| 4 |
Goldman Sachs
New York
|
+$208M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$184M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VOYA Investment Management
Atlanta,
Georgia
|
-$238M |
| 2 |
JP Morgan Chase
New York
|
-$226M |
| 3 |
Comerica Bank
Dallas,
Texas
|
-$217M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$179M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
-$173M |
ABBV Hedge Fund Activity: Q3 2023 in Review
3,110 of the 6,303 institutional investors tracked by Wall St. Rank reported a position in AbbVie (ABBV) for Q3 2023, worth a combined $183B — up 11% from $165B a quarter earlier.
Buyers outnumbered sellers: 175 funds opened new ABBV positions and 106 closed out — a net gain of 69 holders — while 1,277 added to existing stakes and 1,280 trimmed.
The largest buyer was Massachusetts Financial Services, adding an estimated $883M. The largest seller was VOYA Investment Management, cutting an estimated $238M.
- 3,110 institutional investors held AbbVie (ABBV) as of Q3 2023, up from 3,078 in Q2 2023.
- Funds reported $183B of AbbVie stock for Q3 2023, up 11% quarter-over-quarter.
- 175 funds opened new AbbVie positions in Q3 2023 and 106 closed out, a net change of +69 holders.
- The largest AbbVie buyer in Q3 2023 was Massachusetts Financial Services, an estimated $883M added.
- The largest AbbVie seller in Q3 2023 was VOYA Investment Management, an estimated $238M sold.
Based on aggregated 13F filings for Q3 2023.